← Back to Search

Celecoxib for Obsessive-Compulsive Disorder (ACE-OCD Trial)

Q: What indications is Celecoxib usually employed to treat?

<p>Celecoxib is a helpful treatment for managing <a href="https://www.withpower.com/clinical-trials/pain">pain</a>, primary dysmenorrhoea, and <a href="https://www.withpower.com/clinical-trials/rheumatoid-arthritis">rheumatoid arthritis</a>.</p>

Phase 2

Recruiting

Led By S. Evelyn Stewart, MD

Research Sponsored by University of British Columbia

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be younger than 65 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 6 weeks, 12 weeks

Awards & highlights

ACE-OCD Trial Summary

This trial will compare the effectiveness of celecoxib to placebo as an additional treatment for children and youth with moderate to severe OCD.

Eligible Conditions

Obsessive-Compulsive Disorder
Mental Health Disorder

ACE-OCD Trial Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 6 weeks, 12 weeks

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~6 weeks, 12 weeks

This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 weeks, 12 weeks for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Secondary outcome measures

Children's Yale-Brown Obsessive-Compulsive Scale, 1st Edition (CY-BOCS-I)

Mean Clinical Global Impression of Severity (CGI-S)

Mean Clinician Global Impression of Improvement (CGI-I)

+3 more

Side effects data

From 2010 Phase 2 trial • 255 Patients • NCT01062113

Beta 2 microglobulin increased

Beta-N-acetyl-D-glucosaminidase increased

Blood bilirubin increased

Eczema

White blood cell count increased

Blood urine present

Hypoaesthesia facial

Rash

Post procedural haemorrhage

Blood creatine phosphokinase increased

Blood phosphorus decreased

Urobilin urine present

Presyncope

Somnolence

100%

80%

60%

40%

20%

Study treatment Arm

Initial Dose Celecoxib 400 mg

Additional Dose Placebo

Additional Dose Celecoxib 200 mg

ACE-OCD Trial Design

2Treatment groups

Experimental Treatment

Placebo Group

Group I: CelecoxibExperimental Treatment1 Intervention

Celecoxib 50 mg orally twice daily (if weight 10-25 kg) or 100 mg orally twice daily (if weight > 25 kg) for 12 weeks. Used as adjunct to treatment-as-usual.

Group II: Placebo (microcrystalline cellulose)Placebo Group1 Intervention

Placebo capsules identical to celecoxib. One capsule orally twice daily for 12 weeks. Used as adjunct to treatment-as-usual.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Celecoxib

FDA approved

Do I qualify?Apply below to find out

Find a Location

Who is running the clinical trial?

University of British ColumbiaLead Sponsor

1,413 Previous Clinical Trials

2,466,881 Total Patients Enrolled

6 Trials studying Obsessive-Compulsive Disorder

753 Patients Enrolled for Obsessive-Compulsive Disorder

BC Children's Hospital Research InstituteOTHER

12 Previous Clinical Trials

2,262 Total Patients Enrolled

Obsessive Compulsive FoundationOTHER

6 Previous Clinical Trials

173 Total Patients Enrolled

6 Trials studying Obsessive-Compulsive Disorder

173 Patients Enrolled for Obsessive-Compulsive Disorder

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What indications is Celecoxib usually employed to treat?

"Celecoxib is a helpful treatment for managing pain, primary dysmenorrhoea, and rheumatoid arthritis."

Answered by AI

What is the upper limit on participation in this research endeavor?

"Affirmative. The information on clinicaltrials.gov presents evidence that this medical trial is currently enrolling participants. It was first posted on June 1st, 2021 and has been newly updated as of July 22nd 2022. 80 subjects are needed from one site to complete the study's requirements."

Answered by AI

Are newly enrolled participants still being accepted in this clinical investigation?

"Affirmative. The information hosted on clinicaltrials.gov indicates that this trial, which was originally announced on June 1st 2021, is actively seeking participants to enrol in the study. 80 people are sought from a single medical centre for this experiment."

Answered by AI

Does the age requirement for this trial exceed fifty years of age?

"According to the study parameters, only individuals aged 7 - 18 can participate in this medical trial."

Answered by AI

Is there an opportunity for me to join this medical experiment?

"Eligible candidates for this medical study must meet a few requirements. They need to be 7-18 years of age, live in British Columbia, have an established DSM-5 diagnosis of OCD based on prior clinician assessment and/or standardized interview, display moderate to severe levels (CY-BOCS score ≥16) of the disorder's symptoms, take medication twice daily orally or by capsule form if needed, pass a pregnancy test if applicable and use highly effective contraception methods. In total 80 participants will join this OCBD trial."

Answered by AI

Has Celecoxib been verified as safe and effective by the FDA?

"Celecoxib's safety profile was judged to be a 2 on the scale of 1-3, since this is only a Phase 2 trial with some existing data backing its security but none endorsing efficacy."

Answered by AI

Recent research and studies

formation/NLM/NIH, NCBI. “Gprobe”. 2017. Web. <https://github.com/ncbi/gprobe>..Journal

Gprobe

Information/NLM/NIH, NCBI. 2017. “Gprobe”. GitHub repository. https://github.com/ncbi/gprobe.

clinicaltrials.govStudy

Adjunctive Celecoxib in Childhood-onset OCD Study

Evelyn Stewart, MD 2021. "Adjunctive Celecoxib in Childhood-onset OCD Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04673578.

All > Ocd